Immutep (ASX:IMM) reported progress in its study evaluating the effectiveness of IMP761 in treating autoimmune diseases, with the trial now moving to the Part B dose escalation phase, according to a Thursday filing with the Australian bourse.
This follows the completion of Part A of the placebo-controlled, double-blind first-in-human Phase I study, with no safety issues identified during the single-dose administration.
Dosing under Phase B will move from 0.03 mg/kg up to 0.90 mg/kg.
The clinical-stage biotechnology company expects to acquire the study's first safety data before the end of the year.
Immutep's shares inched up 2% in recent trade.
Price (AUD): $0.31, Change: $+0.0050, Percent Change: +1.64%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。